{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T14:40:00Z","timestamp":1756305600849,"version":"3.44.0"},"reference-count":27,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2018,12,21]]},"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:p>We describe three cases of pulmonary aspergillosis (PA) in three patients without traditional risk factors for invasive aspergillosis infection, such as prolonged neutropenia or high dose systemic corticosteroid therapy. All three patients developed PA while taking tyrosine kinase inhibitors (TKI) and sustained greater clinical improvement once TKI were withdrawn. Our case series supports the theory TKI treatment can increase susceptibility to PA without causing neutropenia. Recognition that TKI treatment may predispose to invasive aspergillosis will allow for rapid recognition of affected patients and more effective management of future cases.<\/jats:p>","DOI":"10.1136\/bcr-2018-226121","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T23:09:32Z","timestamp":1548889772000},"page":"e226121","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Invasive aspergillosis complicating treatment with tyrosine kinase inhibitors"],"prefix":"10.1136","volume":"12","author":[{"given":"Tajwar","family":"Nasir","sequence":"first","affiliation":[{"name":"Respiratory Division of Medicine, University College London Medical School, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Lee","sequence":"additional","affiliation":[{"name":"Respiratory Division of Medicine, University College London Medical School, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra SC","family":"Lawrence","sequence":"additional","affiliation":[{"name":"Respiratory Division of Medicine, University College London Hospital, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy S","family":"Brown","sequence":"additional","affiliation":[{"name":"Respiratory Division of Medicine, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,1,29]]},"reference":[{"key":"2025082707231450000_12.1.e226121.1","doi-asserted-by":"crossref","unstructured":"Xing L . Clinical candidates of small molecule p38 MAPK inhibitors for inflammatory diseases. MAP Kinase 2016;4.doi:10.4081\/mk.2015.5508","DOI":"10.4081\/mk.2015.5508"},{"key":"2025082707231450000_12.1.e226121.2","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1517\/14656566.2014.911286","article-title":"New RAF kinase inhibitors in cancer therapy","volume":"15","author":"Martin-Liberal","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"2025082707231450000_12.1.e226121.3","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.058388"},{"key":"2025082707231450000_12.1.e226121.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.24485"},{"key":"2025082707231450000_12.1.e226121.5","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.cmi.2018.02.009","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)","volume":"24 Suppl 2","author":"Reinwald","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2025082707231450000_12.1.e226121.6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2012.06829.x"},{"key":"2025082707231450000_12.1.e226121.7","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.7150\/ijms.6824","article-title":"Risk factors for invasive pulmonary aspergillosis and hospital mortality in acute-on-chronic liver failure patients: a retrospective-cohort study","volume":"10","author":"Chen","year":"2013","journal-title":"Int J Med Sci"},{"key":"2025082707231450000_12.1.e226121.8","unstructured":"Ghez D , Calleja A , Protin C , et al . Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 2018 Feb 1. Blood 2017:11\u2013818286."},{"key":"2025082707231450000_12.1.e226121.9","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy175"},{"key":"2025082707231450000_12.1.e226121.10","first-page":"27","article-title":"Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia","volume":"21","author":"Arthurs","year":"2017","journal-title":"Respir Med Case Rep"},{"key":"2025082707231450000_12.1.e226121.11","article-title":"Cerebral aspergillosis in a patient on ibrutinib therapy\u2014A predisposition not to overlook","volume":"17","author":"Faisal","year":"2018","journal-title":"Journal of Oncology Pharmacy Practice"},{"key":"2025082707231450000_12.1.e226121.12","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/hon.2387","article-title":"Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma","volume":"36","author":"Kreiniz","year":"2018","journal-title":"Hematol Oncol"},{"key":"2025082707231450000_12.1.e226121.13","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.cmi.2018.01.028","article-title":"Invasive aspergillosis with pulmonary and central nervous system involvement during ibrutinib therapy for relapsed chronic lymphocytic leukaemia: case report","volume":"24","author":"Peri","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2025082707231450000_12.1.e226121.14","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1080\/10428194.2017.1320710","article-title":"Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis","volume":"58","author":"Baron","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"2025082707231450000_12.1.e226121.15","first-page":"1","article-title":"Disseminated cryptococcal disease in a patient with chronic lymphocytic leukemia on ibrutinib","volume":"2016","author":"Okamoto","year":"2016","journal-title":"Case Rep Infect Dis"},{"key":"2025082707231450000_12.1.e226121.16","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw261","article-title":"Disseminated cryptococcosis with brain involvement in patients with chronic lymphoid malignancies on ibrutinib","volume":"4","author":"Messina","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2025082707231450000_12.1.e226121.17","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1164\/rccm.201703-0601IM","article-title":"Pulmonary cryptococcus presenting as a solitary pulmonary nodule","volume":"196","author":"Sudhakaran","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2025082707231450000_12.1.e226121.18","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-224786","article-title":"Cryptococcus neoformans empyema in a patient receiving ibrutinib for diffuse large B-cell lymphoma and a review of the literature","volume":"2018","author":"Swan","year":"20182018","journal-title":"BMJ Case Rep"},{"key":"2025082707231450000_12.1.e226121.19","doi-asserted-by":"crossref","unstructured":"Stankowicz M , Banaszynski M , Crawford R . Cryptococcal infections in two patients receiving ibrutinib therapy for chronic lymphocytic leukemia. J Oncol Pharm Pract 2018:107815521775207.doi:10.1177\/1078155217752078","DOI":"10.1177\/1078155217752078"},{"key":"2025082707231450000_12.1.e226121.20","doi-asserted-by":"crossref","first-page":"62","DOI":"10.14740\/wjon1099w","article-title":"Cutaneous mucormycosis following a bullous pemphigoid flare in a chronic lymphocytic leukemia patient on ibrutinib","volume":"9","author":"Stein","year":"2018","journal-title":"World J Oncol"},{"key":"2025082707231450000_12.1.e226121.21","doi-asserted-by":"crossref","first-page":"E646","DOI":"10.1002\/ajh.24890","article-title":"Ibrutinib-associated Pneumocystis jirovecii pneumonia","volume":"92","author":"Lee","year":"2017","journal-title":"Am J Hematol"},{"key":"2025082707231450000_12.1.e226121.22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-722991"},{"key":"2025082707231450000_12.1.e226121.23","first-page":"365","article-title":"Mucormycosis during Imatinib treatment: case report","volume":"8","author":"Crisan","year":"2015","journal-title":"J Med Life"},{"key":"2025082707231450000_12.1.e226121.24","doi-asserted-by":"publisher","DOI":"10.1080\/13693780701558969"},{"key":"2025082707231450000_12.1.e226121.25","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201404556"},{"key":"2025082707231450000_12.1.e226121.26","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma","volume":"31","author":"Lionakis","year":"2017","journal-title":"Cancer Cell"},{"key":"2025082707231450000_12.1.e226121.27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003446"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2018-226121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T14:23:24Z","timestamp":1756304604000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2018-226121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1,29]]},"published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1136\/bcr-2018-226121"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2018-226121","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}